ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v23i4.3083ppharm-2873Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWНовые перспективы применения ОМ-85: обзор литературыNew Prospects for the Application of Om-85: A Literature Reviewhttps://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Намазова-Баранова Лейла Сеймуровна - д.м.н., профессор, академик РАН.

Москва, Шэньчжэнь

Moscow, Shenzhen

leyla.s.namazova@gmail.comhttps://orcid.org/0000-0003-1649-5493ДомашеваП. А.DomashevaPolina A.

Домашева Полина Александровна - аспирант рниму им. Н.И. Пирогова (Пироговский Университет), лаборант-исследователь НИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского».

119333, Москва, ул. Фотиевой, д. 10, стр. 1, тел.: +7 (989) 854-74-82

Moscow

polinapzh@mail.ruhttps://orcid.org/0000-0003-0317-2425ЭфендиеваК. Е.EfendievaKamilla E.

Эфендиева Камилла Евгеньевна - к.м.н.

Москва

Moscow

kamillaef@inbox.ruНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова (Пироговский Университет); Университет МГУ-ППИ в ШэньчжэнеРоссияPediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical University; Shenzhen MSU-BIT UniversityRussian FederationНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова (Пироговский Университет)РоссияPediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical UniversityRussian Federation202609102026234466475Copyright © Намазова-Баранова Л.С., Домашева П.А., Эфендиева К.Е., 20262026Намазова-Баранова Л.С., Домашева П.А., Эфендиева К.Е.Namazova-Baranova L.S., Domasheva P.A., Efendieva K.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2873

Бактериальный лизат ОМ-85 — хорошо изученный иммуномодулятор с благоприятным профилем безопасности. Его эффективность в профилактике и комплексной терапии рецидивирующих респираторных инфекций у детей подтверждена результатами многочисленных клинических исследований, в которых продемонстрировано снижение частоты инфекций, потребности в антибактериальной терапии и продолжительности заболеваний. ОМ-85 активирует синтез интерферонов, усиливает продукцию секреторного IgA и модулирует баланс T-хелперного (Th) ответа, способствуя его смещению в сторону Th1-типа и активации регуляторных T-клеток. Эти иммуномодулирующие свойства открывают перспективы применения препарата в составе комплексной терапии T2-опосредованных заболеваний, включая бронхиальную астму, аллергический ринит и атопический дерматит. К перспективным направлениям дальнейших исследований относятся оценка эффективности пролонгированных курсов применения ОМ-85 продолжительностью до 6–9 мес, а также изучение его роли в первичной профилактике аллергических заболеваний. Таким образом, потенциал ОМ-85 не ограничивается профилактикой респираторных инфекций и может быть связан с разработкой новых подходов к контролю широкого спектра иммуноопосредованных заболеваний.

The bacterial lysate OM-85 is a well-studied immunomodulator with a favorable safety profile. Its efficacy in the prevention and combination therapy of recurrent respiratory infections in children has been confirmed by numerous clinical trials, which have demonstrated a reduction in infection frequency, antibiotic use, and disease duration. Mechanistically, OM-85 induces interferon synthesis, enhances secretory IgA production, and modulates the T-helper (Th) balance by promoting a Th1-skewed response and activating regulatory T cells. These immunomodulatory properties open up prospects for its use as part of combination therapy in T2-mediated conditions, including bronchial asthma, allergic rhinitis, and atopic dermatitis. Promising directions for further research include evaluating the efficacy of extended OM-85 courses lasting up to 6–9 months, as well as investigating its role in the primary prevention of allergic diseases. Thus, the potential of OM-85 is not limited to the prevention of respiratory infections and may extend to the development of novel approaches for managing a broad range of immune-mediated disorders.

детибактериальные лизатыОМ-85Бронхо-муналБронхо-Ваксомострые респираторные инфекциипедиатрияаллергияпрофилактикаchildrenbacterial lysatesOM-85Broncho-MunalBroncho-Vaxomacute respiratory infectionspediatricsallergypreventionОтсутствуетNot specifiedReferencesОстрая респираторная вирусная инфекция (ОРВИ): клинические рекомендации / Союз педиатров России. — М.; 2022. — 42 с. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/25_2. Ссылка активна на 20.11.2025.Ostraya respiratornaya virusnaya infektsiya (ORVI): Clinical guidelines. Union of Pediatricians of Russia. Moscow; 2022. 42 p. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/preview-cr/25_2. Ссылка активна на 20.11.2025.Острые респираторные заболевания у детей: лечение и профилактика: пособие для врачей / под ред. А.А. Баранова. — М.: Международный Фонд охраны здоровья матери и ребенка; 2002. — 70 с.Ostrye respiratornye zabolevaniya u detei: lechenie i profilaktika: lechenie i profilaktika: Manual for doctors. Baranov AA, ed. Moscow: Mezhdunarodnyi Fond okhrany zdorov’ya materi i rebenka; 2002. 70 p. (In Russ).Safiri S, Mahmoodpoor A, Kolahi AA, et al. Global burden of lower respiratory infections during the last three decades. Front Public Health. 2023;10:1028525. doi: https://doi.org/10.3389/fpubh.2022.1028525Safiri S, Mahmoodpoor A, Kolahi AA, et al. Global burden of lower respiratory infections during the last three decades. Front Public Health. 2023;10:1028525. doi: https://doi.org/10.3389/fpubh.2022.1028525Rossi GA, Pohunek P, Feleszko W, et al. Viral infections and wheezing-asthma inception in childhood: is there a role for immunomodulation by oral bacterial lysates? Clin Transl Allergy. 2020;10:17. doi: https://doi.org/10.1186/s13601020-00322-1Rossi GA, Pohunek P, Feleszko W, et al. Viral infections and wheezing-asthma inception in childhood: is there a role for immunomodulation by oral bacterial lysates? Clin Transl Allergy. 2020;10:17. doi: https://doi.org/10.1186/s13601020-00322-1Renz H, Holt PG, Inouye M, et al. An exposome perspective: Earlylife events and immune development in a changing world. J Allergy Clin Immunol. 2017;140(1):24–40. doi: https://doi.org/10.1016/j.jaci.2017.05.015Renz H, Holt PG, Inouye M, et al. An exposome perspective: Earlylife events and immune development in a changing world. J Allergy Clin Immunol. 2017;140(1):24–40. doi: https://doi.org/10.1016/j.jaci.2017.05.015Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn Children. Cell. 2018;174(5):1277–1292. e14. doi: https://doi.org/10.1016/j.cell.2018.06.045Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn Children. Cell. 2018;174(5):1277–1292. e14. doi: https://doi.org/10.1016/j.cell.2018.06.045Groves HE, Piché-Renaud PP, Peci A, et al. The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A populationbased study. Lancet Reg Health Am. 2021;1:100015. doi: https://doi.org/10.1016/j.lana.2021.100015Groves HE, Piché-Renaud PP, Peci A, et al. The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A populationbased study. Lancet Reg Health Am. 2021;1:100015. doi: https://doi.org/10.1016/j.lana.2021.100015Ryan FJ, Hope CM, Masavuli MG, et al. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. 2022;20(1):26. doi: https://doi.org/10.1186/s12916021-02228-6Ryan FJ, Hope CM, Masavuli MG, et al. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. 2022;20(1):26. doi: https://doi.org/10.1186/s12916021-02228-6Львов Д.К., Бурцева Е.И., Колобухина Л.В. и др. Особенности циркуляции вирусов гриппа и ОРВИ в эпидемическом сезоне 2019–2020 гг. в отдельных регионах России // Вопросы вирусологии. — 2020. — Т. 65. — № 6. — С. 335–349. — doi: https://doi.org/10.36233/0507-4088-2020-65-6-4L’vov DK, Burtseva EI, Kolobukhina LV, et al. Peculiarities of the influenza and ARVI viruses during epidemic season 2019–2020 in some regions of Russia. Problems of Virology = Voprosy Virusologii. 2020;65(6):335–349. (In Russ). doi: https://doi.org/10.36233/0507-4088-202065-6-4Corsello A, Milani GP, Picca M, et al. Recurrent upper respiratory tract infections in early childhood: a newly defined clinical condition. Ital J Pediatr. 2024;50(1):30. doi: https://doi.org/10.1186/s13052-024-01600-5Corsello A, Milani GP, Picca M, et al. Recurrent upper respiratory tract infections in early childhood: a newly defined clinical condition. Ital J Pediatr. 2024;50(1):30. doi: https://doi.org/10.1186/s13052-024-01600-5Collaro AJ, McElrea MS, Marchant JM, et al. The effect of early childhood respiratory infections and pneumonia on lifelong lung function: a systematic review. Lancet Child Adolesc Health. 2023;7(6):429–440. doi: https://doi.org/10.1016/S2352-4642(23)00030-5Collaro AJ, McElrea MS, Marchant JM, et al. The effect of early childhood respiratory infections and pneumonia on lifelong lung function: a systematic review. Lancet Child Adolesc Health. 2023;7(6):429–440. doi: https://doi.org/10.1016/S2352-4642(23)00030-5Mukozheva RA, Kulichenko TV, Vilchanskaya TV, et al. Outpatient Management of Acute Respiratory Infections in Children. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2021;18(5):359–366. (In Russ). doi: https://doi.org/10.15690/pf.v18i5.2298Mukozheva RA, Kulichenko TV, Vilchanskaya TV, et al. Outpatient Management of Acute Respiratory Infections in Children. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2021;18(5):359–366. (In Russ). doi: https://doi.org/10.15690/pf.v18i5.2298]Del-Rio-Navarro BE, Espinosa Rosales F, Flenady V, SienraMonge JJ. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev. 2006;(4):CD004974. doi: https://doi.org/10.1002/14651858.CD004974.pub2Del-Rio-Navarro BE, Espinosa Rosales F, Flenady V, SienraMonge JJ. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev. 2006;(4):CD004974. doi: https://doi.org/10.1002/14651858.CD004974.pub2Di Gioacchino M, Santilli F, Pession A. Is There a Role for Immunostimulant Bacterial Lysates in the Management of Respiratory Tract Infection? Biomolecules. 2024;14(10):1249. doi: https://doi.org/10.3390/biom14101249Di Gioacchino M, Santilli F, Pession A. Is There a Role for Immunostimulant Bacterial Lysates in the Management of Respiratory Tract Infection? Biomolecules. 2024;14(10):1249. doi: https://doi.org/10.3390/biom14101249Rozy A, Chorostowska-Wynimko J. Bacterial immunostimulants--mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol. 2008;76(5):353–359.Rozy A, Chorostowska-Wynimko J. Bacterial immunostimulants--mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol. 2008;76(5):353–359.Zhu LL, Wang YH, Feng JH, et al. Oral Bacterial Lysate OM-85: Advances in Pharmacology and Therapeutics. Drug Des Devel Ther. 2024;18:4387–4399. doi: https://doi.org/10.2147/DDDT.S484897Zhu LL, Wang YH, Feng JH, et al. Oral Bacterial Lysate OM-85: Advances in Pharmacology and Therapeutics. Drug Des Devel Ther. 2024;18:4387–4399. doi: https://doi.org/10.2147/DDDT.S484897Esposito S, Cassano M, Cutrera R, et al. Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study. Hum Vaccin Immunother. 2022;18(6):2106720. doi: https://doi.org/10.1080/21645515.2022.2106720Esposito S, Cassano M, Cutrera R, et al. Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study. Hum Vaccin Immunother. 2022;18(6):2106720. doi: https://doi.org/10.1080/21645515.2022.2106720Luan H, Zhang Q, Wang L, et al. OM85-BV induced the productions of IL-1β, IL-6, and TNF-α via TLR4and TLR2-mediated ERK1/2/ NFB pathway in RAW264.7 cells. J Interferon Cytokine Res. 2014;34(7):526–536. doi: https://doi.org/10.1089/jir.2013.0077Luan H, Zhang Q, Wang L, et al. OM85-BV induced the productions of IL-1β, IL-6, and TNF-α via TLR4and TLR2-mediated ERK1/2/ NFB pathway in RAW264.7 cells. J Interferon Cytokine Res. 2014;34(7):526–536. doi: https://doi.org/10.1089/jir.2013.0077Parola C, Salogni L, Vaira X, et al. Selective activation of human dendritic cells by OM-85 through a NF-kB and MAPK dependent pathway. PLoS One. 2013;8(12):e82867. doi: https://doi.org/10.1371/journal.pone.0082867Parola C, Salogni L, Vaira X, et al. Selective activation of human dendritic cells by OM-85 through a NF-kB and MAPK dependent pathway. PLoS One. 2013;8(12):e82867. doi: https://doi.org/10.1371/journal.pone.0082867Cardinale F, Lombardi E, Rossi O, et al. Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85. Expert Rev Respir Med. 2020;14(10):1019– 1026. doi: https://doi.org/10.1080/17476348.2020.1793673Cardinale F, Lombardi E, Rossi O, et al. Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85. Expert Rev Respir Med. 2020;14(10):1019– 1026. doi: https://doi.org/10.1080/17476348.2020.1793673Rahman MM, Grice ID, Ulett GC, Wei MQ. Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer. J Immunol Res. 2024;2024:4312908. doi: https://doi.org/10.1155/2024/4312908Rahman MM, Grice ID, Ulett GC, Wei MQ. Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer. J Immunol Res. 2024;2024:4312908. doi: https://doi.org/10.1155/2024/4312908Huber M, Mossmann H, Bessler WG. Th1-orientated immunological properties of the bacterial extract OM-85-BV. Eur J Med Res. 2005;10(5):209–217.Huber M, Mossmann H, Bessler WG. Th1-orientated immunological properties of the bacterial extract OM-85-BV. Eur J Med Res. 2005;10(5):209–217.Dang AT, Pasquali C, Ludigs K, Guarda G. OM-85 is an immunomodulator of interferon-β production and inflammasome activity. Sci Rep. 2017;7:43844. doi: https://doi.org/10.1038/srep43844Dang AT, Pasquali C, Ludigs K, Guarda G. OM-85 is an immunomodulator of interferon-β production and inflammasome activity. Sci Rep. 2017;7:43844. doi: https://doi.org/10.1038/srep43844Yin J, Xu B, Zeng X, Shen K. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis. Int Immunopharmacol. 2018;54:198–209. doi: https://doi.org/10.1016/j.intimp.2017.10.032Yin J, Xu B, Zeng X, Shen K. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis. Int Immunopharmacol. 2018;54:198–209. doi: https://doi.org/10.1016/j.intimp.2017.10.032Esposito S, Soto-Martinez ME, Feleszko W, et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018;18(3):198209. doi: https://doi.org/10.1097/ACI.0000000000000433Esposito S, Soto-Martinez ME, Feleszko W, et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018;18(3):198209. doi: https://doi.org/10.1097/ACI.0000000000000433Schaad UB. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr. 2010;6(1):5–12. doi: https://doi.org/10.1007/s12519-010-0001-xSchaad UB. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr. 2010;6(1):5–12. doi: https://doi.org/10.1007/s12519-010-0001-xSteurer-Stey C, Lagler L, Straub DA, et al. Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. Eur J Pediatr. 2007;166(4):365–376. doi: https://doi.org/10.1007/s00431-006-0248-3Steurer-Stey C, Lagler L, Straub DA, et al. Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. Eur J Pediatr. 2007;166(4):365–376. doi: https://doi.org/10.1007/s00431-006-0248-3De la Torre González C, Pacheco Ríos A, Escalante Domínguez AJ, et al. Comparative metaanalysis of immunoestimulant agents used in pediatric patients in Mexico. Rev Alerg Mex. 2005;52(1):25–38.De la Torre González C, Pacheco Ríos A, Escalante Domínguez AJ, et al. Comparative metaanalysis of immunoestimulant agents used in pediatric patients in Mexico. Rev Alerg Mex. 2005;52(1):25–38.Cao C, Wang J, Li Y, et al. Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis. Int J Clin Pract. 2021;75(5):e13981. doi: https://doi.org/10.1111/ijcp.13981Cao C, Wang J, Li Y, et al. Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis. Int J Clin Pract. 2021;75(5):e13981. doi: https://doi.org/10.1111/ijcp.13981Esposito S, Bianchini S, Bosis S, et al. A randomized, placebocontrolled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. J Transl Med. 2019;17(1):284. doi: https://doi.org/10.1186/s12967-019-2040-yEsposito S, Bianchini S, Bosis S, et al. A randomized, placebocontrolled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. J Transl Med. 2019;17(1):284. doi: https://doi.org/10.1186/s12967-019-2040-yEsposito S, Ballarini S, Argentiero A, et al. Microbiota profiles in pre-school children with respiratory infections: Modification induced by the oral bacterial lysate OM-85. Front Cell Infect Microbiol 2022;12:789436. doi: https://doi.org/10.3389/fcimb.2022.789436Esposito S, Ballarini S, Argentiero A, et al. Microbiota profiles in pre-school children with respiratory infections: Modification induced by the oral bacterial lysate OM-85. Front Cell Infect Microbiol 2022;12:789436. doi: https://doi.org/10.3389/fcimb.2022.789436Foshina EP, Kostinov MP, Poddubikov AV. Influence of bacterial vaccines on the nasopharyngeal microbiocenosis state and evaluation of their clinical efficacy in children with chronic rhinosinusitis and tonsillopharyngitis. Pediatria. Journal n.a. G.N. Speransky. 2018;97(2):129–133. (In Russ). doi: https://doi.org/10.24110/0031-403X-2018-97-2-129-133Foshina EP, Kostinov MP, Poddubikov AV. Influence of bacterial vaccines on the nasopharyngeal microbiocenosis state and evaluation of their clinical efficacy in children with chronic rhinosinusitis and tonsillopharyngitis. Pediatria. Journal n.a. G.N. Speransky. 2018;97(2):129–133. (In Russ). doi: https://doi.org/10.24110/0031-403X-2018-97-2-129-133Chuvirova AG, Yartsev MN. Clinical and immunological characteristic of children with recurrent episodes of acute laryngotracheitis, acute respiratory infections, otorhinolaryngological deseases. Allergology and Immunology in Paediatrics. 2023;(2):33–43. (In Russ). doi: https://doi.org/10.53529/2500-1175-2023-2-33-43Chuvirova AG, Yartsev MN. Clinical and immunological characteristic of children with recurrent episodes of acute laryngotracheitis, acute respiratory infections, otorhinolaryngological deseases. Allergology and Immunology in Paediatrics. 2023;(2):33–43. (In Russ). doi: https://doi.org/10.53529/2500-1175-2023-2-33-43Buendía JA, Patiño DG, Lindarte EF. OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis. BMC Pulm Med. 2022;22(1):465. doi: https://doi.org/10.1186/s12890-02202264-9Buendía JA, Patiño DG, Lindarte EF. OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis. BMC Pulm Med. 2022;22(1):465. doi: https://doi.org/10.1186/s12890-02202264-9Shamsheva OV, Kladova OV, El’shina GA. Profilaktika grippa i ostrykh respiratornykh zabolevanii sochetannym vvedeniem vaktsiny Inflyuvak i bakterial’nogo lizata IRS-19. Detskie infektsii. 2002;(1):65–67. (In Russ).Shamsheva OV, Kladova OV, El’shina GA. Profilaktika grippa i ostrykh respiratornykh zabolevanii sochetannym vvedeniem vaktsiny Inflyuvak i bakterial’nogo lizata IRS-19. Detskie infektsii. 2002;(1):65–67. (In Russ).Kalyuzhin OV. OM-85 in the prevention/treatment of respiratory infections and exacerbations of chronic lung diseases: selection criteria, mechanisms and evidence. Lechaschi Vrach. 2018;(3):77–82. (In Russ).Kalyuzhin OV. OM-85 in the prevention/treatment of respiratory infections and exacerbations of chronic lung diseases: selection criteria, mechanisms and evidence. Lechaschi Vrach. 2018;(3):77–82. (In Russ).Zagar S, Löfler-Badzek D. Broncho-Vaxom in children with rhinosinusitis: a double-blind clinical trial. ORL J Otorhinolaryngol Relat Spec. 1988;50(6):397–404. doi: https://doi.org/10.1159/000276020Zagar S, Löfler-Badzek D. Broncho-Vaxom in children with rhinosinusitis: a double-blind clinical trial. ORL J Otorhinolaryngol Relat Spec. 1988;50(6):397–404. doi: https://doi.org/10.1159/000276020Berber AC, Del-Rio-Navarro BE. Use of Broncho-Vaxom in private practice: phase IV trial in 587 children. Clin Ther. 1996;18(6):1068– 1079. doi: https://doi.org/10.1159/000276020.10.1016/s0149-2918(96)80062-2Berber AC, Del-Rio-Navarro BE. Use of Broncho-Vaxom in private practice: phase IV trial in 587 children. Clin Ther. 1996;18(6):1068– 1079. doi: https://doi.org/10.1159/000276020.10.1016/s0149-2918(96)80062-2Liu YW, Dong SH, Zhan GY, et al. Analysis of the effect of bacterial lysate and the immunologic mechanism in treating infant bronchiolitis. Eur Rev Med Pharmacol Sci. 2017;21(14):3332–3336.Liu YW, Dong SH, Zhan GY, et al. Analysis of the effect of bacterial lysate and the immunologic mechanism in treating infant bronchiolitis. Eur Rev Med Pharmacol Sci. 2017;21(14):3332–3336.Shen Y. Effect and mechanism of Broncho-Vaxom in the treatment of recurrent respiratory tract infections in children. J Pediatr Pharm. 2014;20(1):32–34.Shen Y. Effect and mechanism of Broncho-Vaxom in the treatment of recurrent respiratory tract infections in children. J Pediatr Pharm. 2014;20(1):32–34.Zhu H, Zhang H, Hu W. Clinical observation on 60 cases of recurrent respiratory tract infections in children treated by Bronchovaxom combined with routine treatment. China Prac Med. 2015;10(7):140–141.Zhu H, Zhang H, Hu W. Clinical observation on 60 cases of recurrent respiratory tract infections in children treated by Bronchovaxom combined with routine treatment. China Prac Med. 2015;10(7):140–141.Chang Y, Liu L, Wang J, et al. Clinical effect of bacterial lysates in the treatment of children with repeated respiratory infections. Int J Pediatr. 2017;44(10):710–713.Chang Y, Liu L, Wang J, et al. Clinical effect of bacterial lysates in the treatment of children with repeated respiratory infections. Int J Pediatr. 2017;44(10):710–713.Kalyuzhin OV, Gorelov AV, Malyavin AG, et al. Efficacy and safety of bacterial lysate OM-85 in the treatment of uncomplicated acute respiratory infections: a double-blind, placebocontrolled, multicenter, randomized trial. Terapevticheskii Arkhiv. 2023;95(10):850–858. (In Russ). doi: https://doi.org/10.26442/00403660.2023.10.202464Kalyuzhin OV, Gorelov AV, Malyavin AG, et al. Efficacy and safety of bacterial lysate OM-85 in the treatment of uncomplicated acute respiratory infections: a double-blind, placebocontrolled, multicenter, randomized trial. Terapevticheskii Arkhiv. 2023;95(10):850–858. (In Russ). doi: https://doi.org/10.26442/00403660.2023.10.202464Tsuge M, Ikeda M, Tsukahara H. Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma. Children (Basel). 2022;9(8):1253. doi: https://doi.org/10.3390/children9081253Tsuge M, Ikeda M, Tsukahara H. Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma. Children (Basel). 2022;9(8):1253. doi: https://doi.org/10.3390/children9081253Lu Y, Li Y, Xu L, et al. Bacterial lysate increases the percentage of natural killer T cells in peripheral blood and alleviates asthma in children. Pharmacology. 2015;95(3-4):139–144. doi: https://doi.org/10.1159/000377683Lu Y, Li Y, Xu L, et al. Bacterial lysate increases the percentage of natural killer T cells in peripheral blood and alleviates asthma in children. Pharmacology. 2015;95(3-4):139–144. doi: https://doi.org/10.1159/000377683Han L, Zheng CP, Sun YQ, et al. A bacterial extract of OM-85 Broncho-Vaxom prevents allergic rhinitis in mice. Am J Rhinol Allergy. 2014;28(2):110–116. doi: https://doi.org/10.2500/ajra.2013.27.4021Han L, Zheng CP, Sun YQ, et al. A bacterial extract of OM-85 Broncho-Vaxom prevents allergic rhinitis in mice. Am J Rhinol Allergy. 2014;28(2):110–116. doi: https://doi.org/10.2500/ajra.2013.27.4021Yao S, Qin R, Song X, et al. Bacterial lysate add-on therapy in adult and childhood asthma: a systematic review and meta-analysis. J Thorac Dis. 2023;15(6):3143–3157. doi: https://doi.org/10.21037/jtd-22-1469Yao S, Qin R, Song X, et al. Bacterial lysate add-on therapy in adult and childhood asthma: a systematic review and meta-analysis. J Thorac Dis. 2023;15(6):3143–3157. doi: https://doi.org/10.21037/jtd-22-1469de Boer GM, Żółkiewicz J, Strzelec KP, et al. Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis. Eur Respir Rev. 2020;29(158):190175. doi: https://doi.org/10.1183/16000617.0175-2019de Boer GM, Żółkiewicz J, Strzelec KP, et al. Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis. Eur Respir Rev. 2020;29(158):190175. doi: https://doi.org/10.1183/16000617.0175-2019Christopoulou ME, Panteli LS, Moisidis JA, et al. Oral Bacterial Lysate OM-85 Prevents Respiratory Tract Infections in Asthma: The OMRIA RWE Study. J Asthma Allergy. 2025;18:891–902. doi: https://doi.org/10.2147/JAA.S517194Christopoulou ME, Panteli LS, Moisidis JA, et al. Oral Bacterial Lysate OM-85 Prevents Respiratory Tract Infections in Asthma: The OMRIA RWE Study. J Asthma Allergy. 2025;18:891–902. doi: https://doi.org/10.2147/JAA.S517194Huang X, Zhang X, Zhang Z, et al. Bacterial lysates in allergic rhinitis and chronic rhinosinusitis: Mechanisms and clinical evidence. Sci Prog. 2025;108(2):368504251355373. doi: https://doi.org/10.1177/00368504251355373Huang X, Zhang X, Zhang Z, et al. Bacterial lysates in allergic rhinitis and chronic rhinosinusitis: Mechanisms and clinical evidence. Sci Prog. 2025;108(2):368504251355373. doi: https://doi.org/10.1177/00368504251355373Meng Q, Li P, Li Y. Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa. Rhinology. 2019;57(6):451–459. doi: https://doi.org/10.4193/Rhin19.161Meng Q, Li P, Li Y. Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa. Rhinology. 2019;57(6):451–459. doi: https://doi.org/10.4193/Rhin19.161Yan H, Hong J, Zeng C, et al. The impact of bacterial lysate (OM85) on clinical and immunological parameters in children with allergic rhinitis. Eur Arch Otorhinolaryngol. 2025;282(11):5703–5709. doi: https://doi.org/10.1007/s00405-025-09728-8Yan H, Hong J, Zeng C, et al. The impact of bacterial lysate (OM85) on clinical and immunological parameters in children with allergic rhinitis. Eur Arch Otorhinolaryngol. 2025;282(11):5703–5709. doi: https://doi.org/10.1007/s00405-025-09728-8Bodemer C, Guillet G, Cambazard F, et al. Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: a randomized study. PLoS One. 2017;12(3):e0161555. doi: https://doi.org/10.1371/journal.pone.0161555Bodemer C, Guillet G, Cambazard F, et al. Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: a randomized study. PLoS One. 2017;12(3):e0161555. doi: https://doi.org/10.1371/journal.pone.0161555Stein MM, Hrusch CL, Gozdz J, et al. Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Engl J Med. 2016;375(5):411–421. doi: https://doi.org/10.1056/NEJMoa1508749Stein MM, Hrusch CL, Gozdz J, et al. Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Engl J Med. 2016;375(5):411–421. doi: https://doi.org/10.1056/NEJMoa1508749Rahbek-Hansen SH, Mikkelsen M, Stokholm J, et al. Preventive effects of prenatal administration of OM-85/BV on asthma and respiratory infection risk in the offspring: A review of animal models. Pediatr Allergy Immunol. 2024;35(6):e14184. doi: https://doi.org/10.1111/pai.14184Rahbek-Hansen SH, Mikkelsen M, Stokholm J, et al. Preventive effects of prenatal administration of OM-85/BV on asthma and respiratory infection risk in the offspring: A review of animal models. Pediatr Allergy Immunol. 2024;35(6):e14184. doi: https://doi.org/10.1111/pai.14184Mincham KT, Scott NM, Lauzon-Joset JF, et al. Transplacental immune modulation with a bacterial-derived agent protects against 4869. doi: https://doi.org/10.1172/JCI122631Mincham KT, Scott NM, Lauzon-Joset JF, et al. Transplacental immune modulation with a bacterial-derived agent protects against 4869. doi: https://doi.org/10.1172/JCI122631Maggi L, Mazzoni A, Capone M, et al. The dual function of ILC2: From host protection to pathogenic players in type 2 asthma. Mol Aspects Med. 2021;80:100981. doi: https://doi.org/10.1016/j.mam.2021.100981Maggi L, Mazzoni A, Capone M, et al. The dual function of ILC2: From host protection to pathogenic players in type 2 asthma. Mol Aspects Med. 2021;80:100981. doi: https://doi.org/10.1016/j.mam.2021.100981Zou W, Ma D, Sun F, et al. Maternal OM-85 administration alleviates offspring allergic airway inflammation by downregulating IL-33/ILC2 axis. Pediatr Allergy Immunol. 2025;36(2):e70044. doi: https://doi.org/10.1111/pai.70044Zou W, Ma D, Sun F, et al. Maternal OM-85 administration alleviates offspring allergic airway inflammation by downregulating IL-33/ILC2 axis. Pediatr Allergy Immunol. 2025;36(2):e70044. doi: https://doi.org/10.1111/pai.70044Kazy Z, Czeizel E. A population-based case-control study of broncho-vaxom use during pregnancy. Orv Hetil. 2005;146(46):2359–2361.Kazy Z, Czeizel E. A population-based case-control study of broncho-vaxom use during pregnancy. Orv Hetil. 2005;146(46):2359–2361.

The authors declare that there are no conflicts of interest present.